DS-1040b
Small molecule
Daiichi SankyoDS-1040b is one of 65 small molecule programs targeting Pulmonary Embolism. It is currently in development.
2
Indications
5
Total Trials
0
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
430 competitors in Ischemic Stroke
#DrugCompanyPhaseTrials
1Proamatine
TakedaPreclinical
Repatha
AmgenPreclinical
Levaquin
WWim Janssens
Preclinical
Xylocaine
CCitius Pharmaceuticals, Inc.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Tylenol
KKenvue Brands
Preclinical
Statins
SanofiPreclinical
Urokinase
Mmedac GmbH
Preclinical
Drug Therapy
MMassachusetts General Hospital
Preclinical
Ginkgo Biloba Extract
NNational Center for Complementary and Integrative Health (NCCIH)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Clopidogrel1 trial
Pulmonary Embolism1 trial
Tics1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DS-1040b. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company